Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Avis Budget Gr ( NASDAQ:CAR ) , Cardiff Oncology ( NASDAQ:CRDF )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of Avis Budget Group, Inc. CAR fell sharply in pre-market trading after the company reported second-quarter financial results.
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Fulcrum Therapeutics ( NASDAQ:FULC ) , Exelixis ( NASDAQ:EXEL )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Whirlpool Corporation WHR fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 earnings guidance.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
― Announced results from the 12 mg dose cohort ( n=16 ) of the Phase 1b PIONEER trial of pociredir in sickle cell disease ( SCD ). pociredir was generally well-tolerated with no treatment-related serious adverse events ...
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
― Robust and clinically meaningful absolute mean fetal hemoglobin ( HbF ) induction of 8.6% from baseline at 12 weeks of treatment. 7 of 16 patients achieved absolute HbF levels greater than ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., July 11, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., June 06, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Fulcrum Therapeutics ( NASDAQ:FULC )
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( the "Company" ) FULC, a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming ...
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( the "Company" ) ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming ...
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
CAMBRIDGE, Mass., May 13, 2025 ( GLOBE NEWSWIRE ) -- CAMP4 Therapeutics Corporation ( "CAMP4" ) ( Nasdaq: CAMP ) , a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., May 09, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 24, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( the "Company" ) ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., April 11, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Fulcrum Therapeutics ( NASDAQ:FULC )
MyoKardia paid Fulcrum $10 million upfront and $2.5 million in prepaid research funding. Fulcrum could have earned up to $298.5 million per target in milestones. Get 5 stock picks identified before their biggest breakouts, identified by the same system that spotted Insmed, Sprouts, and Uber ...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Feb. 07, 2025 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board ...
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - Spero Therapeutics ( NASDAQ:SPRO )
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022
Fulcrum Therapeutics ( FULC ) Upgraded to Buy: Here's Why
Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for November 12th
GGAL, GFI, FULC, DECK and NGD have been added to the Zacks Rank #1 (Strong Buy) List on November 12, 2024.
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET - Fulcrum Therapeutics ( NASDAQ:FULC )
CAMBRIDGE, Mass., Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( the "Company" ) FULC, a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third ...
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
CAMBRIDGE, Mass., Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( the "Company" ) ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that ...
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
FULC is expected to provide updates on its early-stage candidate for SCD, pociredir, in its third-quarter earnings release.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CAMBRIDGE, Mass., Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® ( Nasdaq: FULC ) , a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted ...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Fulcrum Therapeutics ( NASDAQ:FULC )
CAMBRIDGE, Mass., Oct. 11, 2024 ( GLOBE NEWSWIRE ) -- Fulcrum Therapeutics, Inc.® FULC, a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory ...
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.
Pacira's Exparel Receives Permanent New Product-Specific J-Code
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
Zevra Stock Surges Close to 70% in 3 Months: Here's Why
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.
Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics ( FULC ) Looks Ripe for a Turnaround
Fulcrum Therapeutics (FULC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag - Fulcrum Therapeutics ( NASDAQ:FULC ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease ( AxD ) , an ultra-rare neurological disorder.
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the United States.
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 - Fulcrum Therapeutics ( NASDAQ:FULC ) , Biogen ( NASDAQ:BIIB )
Sage Therapeutics, Inc. SAGE announced that partner Biogen BIIB has terminated its rights related to the investigational neurology candidate, SAGE-324. A phase II study on SAGE-324 for treating essential tremor failed to meet the primary endpoint in July. The termination will be effective from ...
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Biohaven ( NYSE:BHVN ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Shares of Biohaven Ltd. BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia ( SCA ) , a rare and debilitating neurodegenerative ...
